Athena Maria Countouriotis M.D.
Net Worth

Last updated:

What is Athena Maria Countouriotis M.D. net worth?

The estimated net worth of Dr. Athena Maria Countouriotis M.D. is at least $27,028,333 as of 9 Feb 2022. He owns shares worth $3,643,159 as insider, has earned $16,605,174 from insider trading and has received compensation worth at least $6,780,000 in Turning Point Therapeutics, Inc..

What is the salary of Athena Maria Countouriotis M.D.?

Dr. Athena Maria Countouriotis M.D. salary is $1,130,000 per year as Pres, Chief Executive Officer & Director in Turning Point Therapeutics, Inc..

How old is Athena Maria Countouriotis M.D.?

Dr. Athena Maria Countouriotis M.D. is 53 years old, born in 1972.

What stocks does Athena Maria Countouriotis M.D. currently own?

As insider, Dr. Athena Maria Countouriotis M.D. owns shares in one company:

Company Title Shares Price per share Total value
Turning Point Therapeutics, Inc. (TPTX) Pres, Chief Executive Officer & Director 47,930 $76.01 $3,643,159

What does Turning Point Therapeutics, Inc. do?

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

TPTX logo
TPTX
Turning Point Therapeutics, Inc.
$76.01

Athena Maria Countouriotis M.D. insider trading

Turning Point Therapeutics, Inc.

Dr. Athena Maria Countouriotis M.D. has made 7 insider trades between 2019-2022, according to the Form 4 filled with the SEC. Most recently he sold 2,971 units of TPTX stock worth $107,847 on 9 Feb 2022.

The largest trade he's ever made was exercising 25,666 units of TPTX stock on 9 Feb 2021. As of 9 Feb 2022 he still owns at least 47,930 units of TPTX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 2,971 $36.3 $107,847
Option
Common Stock 8,942 $3.2 $28,614
Sale
Common Stock 8,942 $137.55 $1,229,999
Sale
Common Stock 8,942 $137.55 $1,229,999
Option
Stock Option (right to buy) 8,942 $3.2 $28,614
Sale
Common Stock 25,392 $136.43 $3,464,129
Option
Common Stock 25,392 $3.2 $81,254
Option
Stock Option (right to buy) 25,392 $3.2 $81,254
Sale
Common Stock 25,392 $136.43 $3,464,129
Option
Common Stock 25,666 $3.2 $82,131
Sale
Common Stock 25,666 $138.49 $3,554,536
Sale
Common Stock 25,666 $138.49 $3,554,536
Option
Stock Option (right to buy) 25,666 $3.2 $82,131
Option
Stock Option (right to buy) 25,666 $3.2 $82,131
Purchase
Common Stock 4,166 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 12,000 N/A N/A

Turning Point Therapeutics key executives

Turning Point Therapeutics, Inc. executives and other stock owners filed with the SEC: